1.
Arch Soc Esp Oftalmol (Engl Ed)
; 98(12): 713-717, 2023 Dec.
Artículo
en Inglés
| MEDLINE
| ID: mdl-37951353
RESUMEN
We describe one case of polypoidal choroidal vasculopathy with persistent subretinal fluid despite multiple treatment with intravitreal Bevacizumab, Ranibizumab and Aflibercept, as well as Aflibercept associated with photodynamic therapy. The patient reached complete resolution after intravitreal Brolucizumab injection, but experienced recurrence of subretinal fluid 12 weeks after discontinuation. Brolucizumab might be an option in treating subretinal fluid after failure of other anti-VEGF agents associated with photodynamic therapy.